Clinical Trials
2 trialsNCT01249105 2016-03-10
MK-2206 for Recurrent Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed